Bromodomain inhibitors: what does the future hold?

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Cancer cells exhibit addiction to oncogene activation and tumor suppressor inactivation, leading to reliance on aberrant signaling and transcription.
• Epigenetic alterations, particularly mutations in epigenetic regulators in hematologic malignancies, create significant vulnerabilities by deregulating transcription.

Purpose of the Study:

• To review the rationale for using bromodomain inhibitors in hematologic malignancies.
• To discuss the evolution and prospects of bromodomain-targeted therapies, including bromodomain and extraterminal domain (BET) proteins and non-BET targets.

Main Methods:

• Literature review of existing research on bromodomain proteins and their inhibitors.
• Evaluation of bromodomain and extraterminal domain (BET) proteins as a prominent family of targets.
• Discussion of emerging strategies like combinatorial targeting, dual-kinase inhibition, and protein degradation technologies.

Main Results:

• Bromodomain proteins recognize acetylated lysine on histones, recruiting transcription complexes and offering a targetable mechanism for transcription regulation.
• Bromodomain inhibitors represent a recent and promising class of epigenetic drugs for hematologic malignancies.
• The review covers established and novel bromodomain inhibitors, including BET and non-BET targeting agents.

Conclusions:

• Targeting bromodomain proteins provides a strategy to inhibit aberrant transcription in cancer, independent of specific epigenetic mutations.
• Future directions include combinatorial therapies, dual-kinase inhibition, selective bromodomain targeting, and protein degradation to enhance therapeutic efficacy.